

Paula Soares

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2206707/paula-soares-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

265
papers

9,636
citations

49
h-index

89
g-index

300
ext. papers

10,899
ext. citations

4.6
avg, IF

5.96
L-index

#	Paper	IF	Citations
265	Subacute and low-dose tributyltin exposure disturbs the mammalian hypothalamus-pituitary-thyroid axis in a sex-dependent manner.. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2022 , 254, 109279	3.2	1
264	The Multifaceted Profile of Thyroid Disease in the Background of DICER1 Germline and Somatic Mutations: Then, Now and Future Perspectives. <i>Journal of Molecular Pathology</i> , 2022 , 3, 1-14	0.4	
263	Performance of the Bethesda System for Reporting Thyroid Cytology in Multi-Institutional Large Cohort of Pediatric Thyroid Nodules: A Detailed Analysis.. <i>Diagnostics</i> , 2022 , 12,	3.8	1
262	LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer. <i>Pathobiology</i> , 2021 , 88, 400-411	3.6	3
261	Follicular Lesions with Papillary Nuclear Characteristics: Differences in Chromatin Detected by Computerized Image Analysis. <i>Archives of Endocrinology and Metabolism</i> , 2021 , 64, 630-635	2.2	1
260	S616-p-DRP1 associates with locally invasive behavior of follicular cell-derived thyroid carcinoma. <i>Endocrine</i> , 2021 , 73, 85-97	4	1
259	Analyzing the Role of DICER1 Germline Variations in Papillary Thyroid Carcinoma. <i>European Thyroid Journal</i> , 2021 , 9, 296-303	4.2	7
258	Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification. <i>Endocrine Pathology</i> , 2021 , 32, 44-62	4.2	5
257	Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	2
256	Epigenomics in Hurthle Cell Neoplasms: Filling in the Gaps Towards Clinical Application. <i>Frontiers in Endocrinology</i> , 2021 , 12, 674666	5.7	2
255	Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 521-535	3	0
254	Genetic Alterations and Clinical Features in Brazilian Patients With Pheochromocytomas and Paragangliomas. <i>Journal of the Endocrine Society</i> , 2021 , 5, A83-A84	0.4	
253	TERTp mutations and p53 expression in head and neck cutaneous basal cell carcinomas with different aggressive features. <i>Scientific Reports</i> , 2021 , 11, 10395	4.9	0
252	Indeterminate thyroid cytology: detecting malignancy using analysis of nuclear images. <i>Endocrine Connections</i> , 2021 , 10, 707-714	3.5	2
251	MOHS micrographic surgery for head and neck nonmelanoma skin cancer: An approach for ENT surgeons. <i>Dermatologic Therapy</i> , 2021 , 34, e14661	2.2	1
250	Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 1837-1846	5.2	2
249	The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab. <i>Scientific Reports</i> , 2021 , 11, 6067	4.9	7

248	LRP1B: A Giant Lost in Cancer Translation. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	1
247	Ubiquitin-Specific Proteases: Players in Cancer Cellular Processes. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	6
246	TERT Promoter Mutational Status in the Management of Cutaneous Melanoma: Comparison with Sentinel Lymph Node Biopsy. <i>Dermatology</i> , 2021 , 1-10	4.4	
245	Review of the current information on erectile dysfunction in hypertensive males with 40 years of age or older. <i>Porto Biomedical Journal</i> , 2020 , 5, e107	1.1	1
244	Clinicopathological Features as Prognostic Predictors of Poor Outcome in Papillary Thyroid Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	8
243	Reliable blood cancer cells telomere length evaluation by qPCR. <i>Cancer Medicine</i> , 2020 , 9, 3153-3162	4.8	7
242	Prognostic Significance of RAS Mutations and P53 Expression in Cutaneous Squamous Cell Carcinomas. <i>Genes</i> , 2020 , 11,	4.2	5
241	Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	15
240	Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review. <i>Diagnostics</i> , 2020 , 10,	3.8	33
239	Evaluation of the role of mitochondria in the non-targeted effects of ionizing radiation using cybrid cellular models. <i>Scientific Reports</i> , 2020 , 10, 6131	4.9	3
238	Head and neck cutaneous basal cell carcinoma: what should the otorhinolaryngology head and neck surgeon care about?. <i>Acta Otorhinolaryngologica Italica</i> , 2020 , 40, 5-18	2.8	4
237	Cancer incidence after childhood irradiation for tinea capitis in a Portuguese cohort. <i>British Journal of Radiology</i> , 2020 , 93, 20180677	3.4	2
236	Relevant dose of the environmental contaminant, tributyltin, promotes histomorphological changes in the thyroid gland of male rats. <i>Molecular and Cellular Endocrinology</i> , 2020 , 502, 110677	4.4	4
235	Clinical Validation of a Urine Test (Uromonitor-V2) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients. <i>Diagnostics</i> , 2020 , 10,	3.8	12
234	Comprehensive Assessment of mRNA Expression across a Large Cohort of Benign and Malignant Thyroid Tumours. <i>Cancers</i> , 2020 , 12,	6.6	5
233	Molecular Aspects of Thyroid Calcification. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
232	Variants of Papillary Thyroid Carcinoma: An Algorithmic Cytomorphology-Based Approach to Cytology Specimens. <i>Acta Cytologica</i> , 2020 , 64, 288-298	3	2
231	Scalp basal cell carcinoma: A different entity?. <i>Dermatologic Therapy</i> , 2019 , 32, e12828	2.2	3

230	Characterization and antitumor activity of the extracellular carbohydrate polymer from the cyanobacterium <i>Synechocystis</i> SigF mutant. <i>International Journal of Biological Macromolecules</i> , 2019 , 136, 1219-1227	7.9	13
229	Differential Expression of HMGA1 and HMGA2 in pituitary neuroendocrine tumors. <i>Molecular and Cellular Endocrinology</i> , 2019 , 490, 80-87	4.4	3
228	Oncocytic thyroid neoplasms: from histology to molecular biology. <i>Diagnostic Histopathology</i> , 2019 , 25, 154-165	0.7	7
227	Interaction of Genetic Variations in and Modulates the Risk of Hashimoto's Thyroiditis. <i>Thyroid</i> , 2019 , 29, 1302-1315	6.2	7
226	Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism. <i>International Journal of Endocrinology</i> , 2019 , 2019, 4518742	2.7	3
225	MON-374 Composite Pheochromocytoma: Look and You Shall Find.... <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	78
224	Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study. <i>Frontiers in Genetics</i> , 2019 , 10, 1237	4.5	21
223	TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 660-669.e6	4.5	16
222	"The other side of the coin": understanding noninvasive follicular tumor with papillary-like nuclear features in unifocal and multifocal settings. <i>Human Pathology</i> , 2019 , 86, 136-142	3.7	11
221	Genomic and transcriptomic characterization of the mitochondrial-rich oncocytic phenotype on a thyroid carcinoma background. <i>Mitochondrion</i> , 2019 , 46, 123-133	4.9	7
220	NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. <i>Endocrine Connections</i> , 2018 , 7, 78-90	3.5	35
219	Multinodular Goiter Progression Toward Malignancy in a Case of DICER1 Syndrome: Histologic and Molecular Alterations. <i>American Journal of Clinical Pathology</i> , 2018 , 149, 379-386	1.9	13
218	Melanoma treatment in review. <i>ImmunoTargets and Therapy</i> , 2018 , 7, 35-49	9	273
217	Tributyltin and Zebrafish: Swimming in Dangerous Water. <i>Frontiers in Endocrinology</i> , 2018 , 9, 152	5.7	7
216	Dynamin-Related Protein 1 at the Crossroads of Cancer. <i>Genes</i> , 2018 , 9,	4.2	50
215	Telomere Maintenance Mechanisms in Cancer. <i>Genes</i> , 2018 , 9,	4.2	56
214	Follicular thyroid lesions: is there a discriminatory potential in the computerized nuclear analysis?. <i>Endocrine Connections</i> , 2018 , 7, 907-913	3.5	3
213	Unraveling molecular targets of bisphenol A and S in the thyroid gland. <i>Environmental Science and Pollution Research</i> , 2018 , 25, 26916-26926	5.1	13

212	CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extension. <i>BMC Cancer</i> , 2018 , 18, 68	4.8	15
211	Liposomal therapies in oncology: does one size fit all?. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 741-755	3.5	16
210	mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and mRNA Expression. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	16
209	The environmental contaminant tributyltin leads to abnormalities in different levels of the hypothalamus-pituitary-thyroid axis in female rats. <i>Environmental Pollution</i> , 2018 , 241, 636-645	9.3	16
208	TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma. <i>Endocrine</i> , 2018 , 61, 489-498	4	11
207	The genetics of cutaneous squamous cell carcinogenesis. <i>European Journal of Dermatology</i> , 2018 , 28, 597-605	0.8	3
206	Tendências do carcinoma espinocelular cutâneo no Hospital de Gaia (2004-20013). <i>Journal of the Portuguese Society of Dermatology and Venereology</i> , 2018 , 76, 279-286	0.8	3
205	Rare Familial Tumours 2018 , 57-77		3
204	Other Rare Tumours and Tumour-Like Lesions 2018 , 79-105		
203	Rare Papillary Thyroid Carcinomas 2018 , 5-25		
202	Small Cell Tumours 2018 , 45-56		
201	Therapeutic Options 2018 , 107-110		
200	Rare Follicular Tumours 2018 , 27-44		
199	Frontiers in endocrine disruption: Impacts of organotin on the hypothalamus-pituitary-thyroid axis. <i>Molecular and Cellular Endocrinology</i> , 2018 , 460, 246-257	4.4	35
198	Age-Associated Mortality Risk in Papillary Thyroid Cancer: Does BRAF Make a Real Difference?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1455-1456	2.2	3
197	OPNa Overexpression Is Associated with Matrix Calcification in Thyroid Cancer Cell Lines. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	12
196	Selenium and Selenoproteins in Immune Mediated Thyroid Disorders. <i>Diagnostics</i> , 2018 , 8,	3.8	17
195	Cribiform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT/ β -catenin pathway. <i>Modern Pathology</i> , 2018 , 31, 1168-1179	9.8	32

194	Is Low-Dose Radiation Exposure a Risk Factor for Atherosclerotic Disease?. <i>Radiation Research</i> , 2018 , 189, 418-424	3.1	6
193	TERT biology and function in cancer: beyond immortalisation. <i>Journal of Molecular Endocrinology</i> , 2017 , 58, R129-R146	4.5	49
192	The role of ablative treatment in differentiated thyroid cancer management. <i>Expert Review of Endocrinology and Metabolism</i> , 2017 , 12, 109-116	4.1	2
191	Hobnail Variant of Papillary Thyroid Carcinoma: Clinicopathologic and Molecular Evidence of Progression to Undifferentiated Carcinoma in 2 Cases. <i>American Journal of Surgical Pathology</i> , 2017 , 41, 854-860	6.7	31
190	TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1898-1907	5.6	77
189	Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer. <i>Hormones and Cancer</i> , 2017 , 8, 314-324	5	9
188	Etiopathogenesis of oncocytomas. <i>Seminars in Cancer Biology</i> , 2017 , 47, 82-94	12.7	7
187	TERT promoter mutations: a genetic signature of benign and malignant thyroid tumours occurring in the context of tinea capitis irradiation. <i>European Journal of Endocrinology</i> , 2017 , 176, 49-55	6.5	7
186	Telomerase and N-Cadherin Differential Importance in Adrenocortical Cancers and Adenomas. <i>Journal of Cellular Biochemistry</i> , 2017 , 118, 2064-2071	4.7	5
185	SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma. <i>PLoS ONE</i> , 2017 , 12, e0180392	3.7	2
184	GLUT1, MCT1/4 and CD147 overexpression supports the metabolic reprogramming in papillary renal cell carcinoma. <i>Histology and Histopathology</i> , 2017 , 32, 1029-1040	1.4	8
183	The Genetics of Papillary Microcarcinomas of the Thyroid: Diagnostic and Prognostic Implications. <i>Current Genomics</i> , 2017 , 18, 244-254	2.6	19
182	Calcitonin receptor expression in medullary thyroid carcinoma. <i>PeerJ</i> , 2017 , 5, e3778	3.1	2
181	Telomeres in Cancer 2017 , 161-170		
180	pmTOR is a marker of aggressiveness in papillary thyroid carcinomas. <i>Surgery</i> , 2016 , 160, 1582-1590	3.6	5
179	TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes. <i>Scientific Reports</i> , 2016 , 6, 29714	4.9	10
178	The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. <i>International Journal of Cancer</i> , 2016 , 139, 414-23	7.5	41
177	Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2016 , 174, 551-61	6.5	18

176	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 264-74	5.6	144
175	Obesity Is Associated With Low NAD(+)/SIRT Pathway Expression in Adipose Tissue of BMI-Discordant Monozygotic Twins. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 275-83	5.6	93
174	Hotspot TERT promoter mutations are rare events in testicular germ cell tumors. <i>Tumor Biology</i> , 2016 , 37, 4901-7	2.9	12
173	ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome. <i>European Journal of Endocrinology</i> , 2016 , 174, R117-26	6.5	50
172	Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior. <i>Oncotarget</i> , 2016 , 7, 52003-52016	3.3	21
171	Thyroid and Parathyroid Glands 2016 , 613-671		
170	TERT promoter mutations in soft tissue sarcomas. <i>International Journal of Biological Markers</i> , 2016 , 31, e62-7	2.8	10
169	Telomerase Activation in Hematological Malignancies. <i>Genes</i> , 2016 , 7,	4.2	20
168	IL6-174 G>C Polymorphism (rs1800795) Association with Late Effects of Low Dose Radiation Exposure in the Portuguese Tinea Capitis Cohort. <i>PLoS ONE</i> , 2016 , 11, e0163474	3.7	4
167	The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype. <i>Genes</i> , 2016 , 7,	4.2	47
166	Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. <i>Melanoma Research</i> , 2016 , 26, 93-9	3.3	42
165	Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes. <i>Cytogenetic and Genome Research</i> , 2016 , 150, 194-207	1.9	41
164	OXPHOS dysfunction regulates integrin- β modifications and enhances cell motility and migration. <i>Human Molecular Genetics</i> , 2015 , 24, 1977-90	5.6	27
163	RE: TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	3
162	Coexistence of TERT promoter and BRAF mutations in papillary thyroid carcinoma: added value in patient prognosis?. <i>Journal of Clinical Oncology</i> , 2015 , 33, 667-8	2.2	33
161	RAF-1 promotes survival of thyroid cancer cells harboring RET/PTC1 rearrangement independently of ERK activation. <i>Molecular and Cellular Endocrinology</i> , 2015 , 415, 64-75	4.4	3
160	Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs). <i>European Journal of Human Genetics</i> , 2015 , 23, 877-9	5.3	23
159	Poorly Differentiated and Undifferentiated Thyroid Carcinomas. <i>Turk Patoloji Dergisi</i> , 2015 , 31 Suppl 1, 48-59	0.6	10

158	Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2015 , 19, 733-45	6.4	15
157	Mitochondrial dynamics protein Drp1 is overexpressed in oncocytic thyroid tumors and regulates cancer cell migration. <i>PLoS ONE</i> , 2015 , 10, e0122308	3.7	126
156	Prognostic biomarkers in thyroid cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014 , 464, 333-46	5.1	42
155	Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas. <i>Journal of Dermatological Science</i> , 2014 , 73, 31-9	4.3	15
154	A polymorphism in the promoter region of the selenoprotein S gene (SEPS1) contributes to Hashimoto's thyroiditis susceptibility. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E719-23	5.6	49
153	Papillary thyroid microcarcinoma: how to diagnose and manage this epidemic?. <i>International Journal of Surgical Pathology</i> , 2014 , 22, 113-9	1.2	37
152	mTOR activation in medullary thyroid carcinoma with RAS mutation. <i>European Journal of Endocrinology</i> , 2014 , 171, 633-40	6.5	27
151	Telomerase promoter mutations in cancer: an emerging molecular biomarker?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014 , 465, 119-33	5.1	80
150	Increased lymphangiogenesis in Riedel thyroiditis (Immunoglobulin G4-related thyroid disease). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014 , 465, 359-64	5.1	8
149	TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E754-65	5.6	357
148	Neonatal extracorporeal membrane oxygenation: Initial experience of Hospital de Sã Joã. <i>Revista Portuguesa De Pneumologia</i> , 2014 , 20, 336-40		2
147	TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 2251-2257	4.3	85
146	Differentiated thyroid cancer in patients with resistance to thyroid hormone syndrome. A novel case and a review of the literature. <i>Frontiers in Molecular Biosciences</i> , 2014 , 1, 10	5.6	9
145	LRP1B (low density lipoprotein receptor-related protein 1B). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2014 ,	2.3	1
144	Thyroid and parathyroid tumours in patients submitted to X-ray scalp epilation during the tinea capitis eradication campaign in the North of Portugal (1950-1963). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014 , 465, 445-52	5.1	10
143	C-cell-derived calcitonin-free neuroendocrine carcinoma of the thyroid: the diagnostic importance of CGRP immunoreactivity. <i>International Journal of Surgical Pathology</i> , 2014 , 22, 530-5	1.2	24
142	Primary squamous cell carcinoma of the thyroid diagnosed as anaplastic carcinoma: failure in fine-needle aspiration cytology?. <i>Case Reports in Pathology</i> , 2014 , 2014, 301780	0.9	13
141	Polymorphisms in the TNFA and IL6 genes represent risk factors for autoimmune thyroid disease. <i>PLoS ONE</i> , 2014 , 9, e105492	3.7	23

140	Frequency of TERT promoter mutations in human cancers. <i>Nature Communications</i> , 2013 , 4, 2185	17.4	590
139	Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors. <i>European Journal of Human Genetics</i> , 2013 , 21, 503-10	5.3	13
138	Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1422-7	5.6	22
137	Stimulated thyroglobulin at recombinant human TSH-aided ablation predicts disease-free status one year later. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 4364-72	5.6	32
136	A founder SDHB mutation in Portuguese paraganglioma patients. <i>Endocrine-Related Cancer</i> , 2013 , 20, L23-6	5.7	10
135	MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism. <i>European Journal of Endocrinology</i> , 2013 , 168, 119-28	6.5	23
134	Genetic alterations in thyroid tumors from patients irradiated in childhood for tinea capitis treatment. <i>European Journal of Endocrinology</i> , 2013 , 169, 673-9	6.5	8
133	Cribiform-morular variant of papillary thyroid carcinoma displaying poorly differentiated features. <i>International Journal of Surgical Pathology</i> , 2013 , 21, 379-89	1.2	29
132	Radiotherapy: radioiodine and external beam irradiation treatment of differentiated thyroid carcinomas 2013 , 78-92		
131	GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells. <i>PeerJ</i> , 2013 , 1, e104	3.1	10
130	Etiopathogenic factors of thyroid cancer 2013 , 46-62		
129	RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas. <i>Histopathology</i> , 2012 , 61, 833-43	7.3	37
128	Melanocytic tumour in a black sheep never exposed to ultraviolet radiation. <i>Journal of Comparative Pathology</i> , 2012 , 146, 160-4	1	3
127	CDX2 Expression in Some Variants of Papillary Thyroid Carcinoma. <i>American Journal of Clinical Pathology</i> , 2012 , 138, 907-9; author reply p.910	1.9	10
126	The biology and the genetics of Hurthle cell tumors of the thyroid. <i>Endocrine-Related Cancer</i> , 2012 , 19, R131-47	5.7	59
125	Survey of 548 oncogenic fusion transcripts in thyroid tumors supports the importance of the already established thyroid fusions genes. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 1154-64	5	17
124	mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E1139-49	5.6	61
123	The mTOR signalling pathway in human cancer. <i>International Journal of Molecular Sciences</i> , 2012 , 13, 1886-918	6.3	508

122	Head and neck basal cell carcinoma prevalence in individuals submitted to childhood X-ray epilation for tinea capitis treatment. <i>European Journal of Dermatology</i> , 2012 , 22, 225-30	0.8	22
121	Paraganglioma of seminal vesicle and chromophobe renal cell carcinoma: a case report and literature review. <i>Sao Paulo Medical Journal</i> , 2012 , 130, 57-60	1.6	12
120	Insights into melanoma: targeting the mTOR pathway for therapeutics. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16, 689-705	6.4	31
119	A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney-Stratakis dyad. <i>Familial Cancer</i> , 2012 , 11, 189-94	3	16
118	TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012 , 460, 587-600	5.1	34
117	Absence of the BRAF and the GRIM-19 mutations in oncocytic (Hürthle cell) solid cell nests of the thyroid. <i>American Journal of Clinical Pathology</i> , 2012 , 137, 612-8	1.9	16
116	STAT3 negatively regulates thyroid tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E2361-70	11.5	99
115	A clear cell renal cell carcinoma inhibiting the response to intravitreal antivascular endothelial growth factor therapy in wet age-related macular disease. <i>Case Reports in Ophthalmology</i> , 2012 , 3, 443-517	0.7	2
114	AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines. <i>PLoS ONE</i> , 2012 , 7, e46869	3.7	17
113	Thyroid hormone as a regulator of tumor induced angiogenesis. <i>Cancer Letters</i> , 2011 , 301, 119-26	9.9	44
112	GRIM-19 function in cancer development. <i>Mitochondrion</i> , 2011 , 11, 693-9	4.9	25
111	Orthovanadate-induced cell death in RET/PTC1-harboring cancer cells involves the activation of caspases and altered signaling through PI3K/Akt/mTOR. <i>Life Sciences</i> , 2011 , 89, 371-7	6.8	26
110	Head and neck lesions in a cohort irradiated in childhood for tinea capitis treatment. <i>Lancet Infectious Diseases</i> , 2011 , 11, 163-4	25.5	13
109	mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. <i>Pigment Cell and Melanoma Research</i> , 2011 , 24, 254-7	4.5	27
108	Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells. <i>Oncogene</i> , 2011 , 30, 1302-17	9.2	59
107	Tumor-in-tumor of the thyroid with basaloid differentiation: a lesion with a solid cell nest neoplastic component?. <i>International Journal of Surgical Pathology</i> , 2011 , 19, 276-80	1.2	17
106	Involvement of p53 in cell death following cell cycle arrest and mitotic catastrophe induced by rotenone. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011 , 1813, 492-9	4.9	31
105	Impact of EGFR genetic variants on glioma risk and patient outcome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 2610-7	4	32

104	The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011 , 459, 265-76	5.1	42
103	Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011 , 459, 595-605	5.1	18
102	Synergistic growth inhibition of cancer cells harboring the RET/PTC1 oncogene by staurosporine and rotenone involves enhanced cell death. <i>Journal of Biosciences</i> , 2011 , 36, 639-48	2.3	9
101	EBV interferes with the sensitivity of Burkitt lymphoma Akata cells to etoposide. <i>Journal of Cellular Biochemistry</i> , 2011 , 112, 200-10	4.7	6
100	Molecular alterations in sporadic primary hyperparathyroidism. <i>Genetics Research International</i> , 2011 , 2011, 275802	0	7
99	How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer. <i>Journal of Thyroid Research</i> , 2011 , 2011, 678357	2.6	11
98	In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp. <i>Endocrine-Related Cancer</i> , 2011 , 18, 401-12	5.7	10
97	Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. <i>British Journal of Ophthalmology</i> , 2011 , 95, 715-9	5.5	26
96	Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. <i>Current Genomics</i> , 2011 , 12, 609-17	2.6	61
95	Alopecia in women submitted to childhood X-ray epilation for tinea capitis treatment. <i>British Journal of Dermatology</i> , 2010 , 163, 643-4	4	4
94	Molecular pathology of thyroid tumors: diagnostic and prognostic relevance. <i>International Journal of Surgical Pathology</i> , 2010 , 18, 209S-212S	1.2	4
93	Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARGamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor. <i>Endocrine-Related Cancer</i> , 2010 , 17, 509-510	5.7	14
92	Hot topics in papillary thyroid carcinoma. <i>International Journal of Surgical Pathology</i> , 2010 , 18, 190S-193S	1.2	1
91	The familial counterparts of follicular cell-derived thyroid tumors. <i>International Journal of Surgical Pathology</i> , 2010 , 18, 233-42	1.2	7
90	Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. <i>Melanoma Research</i> , 2010 , 20, 107-17	3.3	60
89	Multicentre validation study of nucleic acids extraction from FFPE tissues. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010 , 457, 309-17	5.1	82
88	Cribriiform-morular variant of papillary thyroid carcinoma: molecular characterization of a case with neuroendocrine differentiation and aggressive behavior. <i>American Journal of Clinical Pathology</i> , 2009 , 131, 134-42	1.9	56
87	An assessment of the clonality of the components of canine mixed mammary tumours by mitochondrial DNA analysis. <i>Veterinary Journal</i> , 2009 , 182, 269-74	2.5	12

86	Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. <i>BMC Cancer</i> , 2009 , 9, 387	4.8	22
85	Mitochondria and cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009 , 454, 481-95	5.1	40
84	A follicular variant of papillary thyroid carcinoma in struma ovarii. Case report with unique molecular alterations. <i>Histopathology</i> , 2009 , 55, 482-7	7.3	18
83	Is BRAF mutation screening useful for preoperative risk stratification in papillary thyroid cancer?. <i>Future Oncology</i> , 2009 , 5, 1225-9	3.6	3
82	Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer. <i>Experimental Dermatology</i> , 2009 , 18, 548-52	4	4
81	How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer. <i>Journal of Clinical Pathology</i> , 2009 , 62, 414-21	3.9	19
80	BRAF mutation in papillary thyroid carcinoma: a potential target for therapy?. <i>Expert Review of Endocrinology and Metabolism</i> , 2009 , 4, 467-480	4.1	
79	Mitochondria and Oncocytomas 2009 , 193-209		3
78	Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2008 , 69, 683-5	3.4	25
77	Intragenic mutations in thyroid cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008 , 37, 333-62, viii	5.5	76
76	Follicular thyroid carcinoma with an unusual glomeruloid pattern of growth. <i>Human Pathology</i> , 2008 , 39, 1540-7	3.7	15
75	Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation. <i>Molecular Biology of the Cell</i> , 2008 , 19, 4814-25	3.5	39
74	GRIM-19 in Health and Disease. <i>Advances in Anatomic Pathology</i> , 2008 , 15, 46-53	5.1	18
73	Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma. <i>Familial Cancer</i> , 2008 , 7, 141-9	3	26
72	BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. <i>Journal of Pathology</i> , 2008 , 214, 320-7	9.4	38
71	Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. <i>Thyroid</i> , 2007 , 17, 707-15	6.2	71
70	Molecular genetics of papillary thyroid carcinoma: great expectations. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007 , 51, 643-53		23
69	A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007 , 450, 619-26	5.1	11

68	Thyroid hormone receptor beta mutations in the hot-spot region are rare events in thyroid carcinomas. <i>Journal of Endocrinology</i> , 2007 , 192, 83-6	4.7	14
67	PAX8-PPARGgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 213-20	5.6	219
66	The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma. <i>Human Pathology</i> , 2006 , 37, 562-8	3.7	25
65	B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. <i>Human Pathology</i> , 2006 , 37, 781-6	3.7	63
64	Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal. <i>Clinical Endocrinology</i> , 2006 , 64, 659-66	3.4	17
63	H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid. <i>Oncogene</i> , 2006 , 25, 4620-7	9.2	29
62	Diagnostic criteria in well-differentiated thyroid carcinomas. <i>Endocrine Pathology</i> , 2006 , 17, 109-17	4.2	28
61	Hürthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance. <i>International Journal of Surgical Pathology</i> , 2005 , 13, 29-35	1.2	63
60	Mitochondrial D-Loop instability in thyroid tumours is not a marker of malignancy. <i>Mitochondrion</i> , 2005 , 5, 333-40	4.9	26
59	A stem cell role for thyroid solid cell nests. <i>Human Pathology</i> , 2005 , 36, 590-1	3.7	25
58	A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. <i>Human Pathology</i> , 2005 , 36, 694-7	3.7	84
57	Reply to: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. <i>Cancer Letters</i> , 2005 , 230, 149-50	9.9	3
56	Mutation analysis of B-RAF gene in human gliomas. <i>Acta Neuropathologica</i> , 2005 , 109, 207-10	14.3	76
55	Molecular pathology of well-differentiated thyroid carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005 , 447, 787-93	5.1	60
54	Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients age but not with tumour aggressiveness. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005 , 446, 589-95	5.1	225
53	Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. <i>Journal of Pathology</i> , 2005 , 206, 305-11	9.4	33
52	Cystic Tumor of the Atrioventricular Node of the Heart Appears to Be the Heart Equivalent of the Solid Cell Nests (Ultimobranchial Rests) of the Thyroid. <i>American Journal of Clinical Pathology</i> , 2005 , 123, 369-375	1.9	28
51	Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. <i>British Journal of Cancer</i> , 2005 , 92, 1892-8	8.7	168

50	Cystic tumor of the atrioventricular node of the heart appears to be the heart equivalent of the solid cell nests (ultimobranchial rests) of the thyroid. <i>American Journal of Clinical Pathology</i> , 2005 , 123, 369-75	1.9	5
49	Mutated E-cadherin: genomic and functional characterization in thyroid cells from the KAT family. <i>Thyroid</i> , 2004 , 14, 902-9	6.2	6
48	Telomerase expression and proliferative activity suggest a stem cell role for thyroid solid cell nests. <i>Modern Pathology</i> , 2004 , 17, 819-26	9.8	57
47	Core I gene is overexpressed in Hürthle and non-Hürthle cell microfollicular adenomas and follicular carcinomas of the thyroid. <i>BMC Cancer</i> , 2004 , 4, 12	4.8	4
46	BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004 , 444, 572-6	5.1	96
45	BRAF mutations are associated with some histological types of papillary thyroid carcinoma. <i>Journal of Pathology</i> , 2004 , 202, 247-51	9.4	284
44	BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4267-71	5.6	151
43	Vascular invasion in thyroid and gastric carcinomas. <i>Ultrastructural Pathology</i> , 2003 , 27, 41-8	1.3	1
42	Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 4932-7	5.6	24
41	Alterations of the SDHD gene locus in midgut carcinoids. <i>Genes Chromosomes and Cancer</i> , 2003 , 36, 424-5	5	3
40	Immunohistochemical study of heat shock proteins 27, 60 and 70 in the normal human adrenal and in adrenal tumors with suppressed ACTH production. <i>Microscopy Research and Technique</i> , 2003 , 61, 315-23	2.8	15
39	E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. <i>Histopathology</i> , 2003 , 42, 580-7	7.3	71
38	BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. <i>Oncogene</i> , 2003 , 22, 4578-80	9.2	525
37	p63 expression in solid cell nests of the thyroid: further evidence for a stem cell origin. <i>Modern Pathology</i> , 2003 , 16, 43-8	9.8	93
36	Re: Lohrer,H.D., Hieber,L. and Zitzelsberger,H. (2002) Differential mutation frequency in mitochondrial DNA from thyroid tumours. <i>Carcinogenesis</i> , 23, 1577-1582. <i>Carcinogenesis</i> , 2003 , 24, 1155 ^{4.6}		
35	Molecular pathology of papillary, follicular and Hürthle cell carcinomas of the thyroid. <i>Arkhiv Patologii</i> , 2003 , 65, 45-7	0.2	1
34	Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002 , 440, 418-24	5.1	78
33	Mucoepidermoid carcinoma of the thyroid: a tumour histotype characterised by P-cadherin neoexpression and marked abnormalities of E-cadherin/catenins complex. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002 , 440, 498-504	5.1	26

32	Loss of heterozygosity and promoter methylation, but not mutation, may underlie loss of TFF1 in gastric carcinoma. <i>Laboratory Investigation</i> , 2002 , 82, 1319-26	5.9	80
31	P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression. <i>Pathology Research and Practice</i> , 2002 , 198, 449-54	3.4	24
30	Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma. <i>Journal of Medical Genetics</i> , 2002 , 39, 260-5	5.8	34
29	Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. <i>American Journal of Pathology</i> , 2002 , 160, 1857-65	5.8	214
28	Poorly differentiated carcinomas of the thyroid gland: a review of the clinicopathologic features of a series of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. <i>International Journal of Surgical Pathology</i> , 2002 , 10, 123-31	1.2	61
27	Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant. <i>Journal of Pathology</i> , 2001 , 194, 358-66	9.4	55
26	Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations in gastric carcinoma. <i>Genes Chromosomes and Cancer</i> , 2001 , 32, 136-43	5	91
25	Fetal adenomas and minimally invasive follicular carcinomas of the thyroid frequently display a triploid or near triploid DNA pattern. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001 , 438, 336-42	5.1	17
24	E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. <i>Oncogene</i> , 2001 , 20, 1525-8	9.2	219
23	Extended structural variation of a pentanucleotide repeat in the GSTP1 gene: characterisation in a normal population and in thyroid and gastric tumours. <i>European Journal of Human Genetics</i> , 2000 , 8, 540-4	5.3	10
22	Mitochondrial DNA alteration in gastric cancer. <i>Gastroenterology</i> , 2000 , 119, 1808-9	13.3	11
21	Clinicopathologic and Prognostic Significance of the Expression of Mucins, Simple Mucin Antigens and Histo-Blood Group Antigens in Papillary Thyroid Carcinoma. <i>Endocrine Pathology</i> , 1999 , 10, 305-313	4.2	7
20	Papillary Thyroid Carcinoma Overexpresses Fully and Underglycosylated Mucins Together with Native and Sialylated Simple Mucin Antigens and Histo-Blood Group Antigens. <i>Endocrine Pathology</i> , 1999 , 10, 315-324	4.2	8
19	Comments on: mutations in mitochondrial control region DNA in gastric tumours of Japanese patients, Tamura, et al. <i>Eur J Cancer</i> 1999, 35, 316-319. <i>European Journal of Cancer</i> , 1999 , 35, 1407-8	7.5	23
18	E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. <i>European Journal of Cancer Prevention</i> , 1999 , 8, 351	2	9
17	Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?. <i>Journal of Pathology</i> , 1998 , 185, 71-8	9.4	92
16	Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? 1998 , 185, 71		9
15	Benign and malignant thyroid lesions show instability at microsatellite loci. <i>European Journal of Cancer</i> , 1997 , 33, 293-6	7.5	34

14	E-cadherin gene alterations are rare events in thyroid tumors. <i>International Journal of Cancer</i> , 1997 , 70, 32-8	7.5	71
13	Prognostic factors in thyroid carcinomas. <i>Verhandlungen Der Deutschen Gesellschaft Für Pathologie</i> , 1997 , 81, 82-96		17
12	Recent advances in cytometry, cytogenetics and molecular genetics of thyroid tumours and tumour-like lesions. <i>Pathology Research and Practice</i> , 1995 , 191, 304-17	3.4	19
11	Proliferative activity of human thyroid tumors evaluated by proliferating cell nuclear antigen/cyclin immunohistochemical studies. <i>Cancer</i> , 1994 , 73, 2879-81	6.4	9
10	Expression of C-erb B2 in tumours and tumour-like lesions of the thyroid. <i>International Journal of Cancer</i> , 1994 , 56, 459-61	7.5	10
9	Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid. <i>Histopathology</i> , 1994 , 24, 205-10	7.3	55
8	Cytogenetic findings in 18 follicular thyroid adenomas. <i>Cancer Genetics and Cytogenetics</i> , 1993 , 67, 1-6		40
7	Cytogenetic findings in eleven gastric carcinomas. <i>Cancer Genetics and Cytogenetics</i> , 1993 , 68, 42-8		48
6	Thyroid nodular hyperplasia: chromosomal studies in 14 cases. <i>Cancer Genetics and Cytogenetics</i> , 1993 , 69, 31-4		25
5	Signet ring cell carcinoma of the stomach: a morphometric, ultrastructural, and DNA cytometric study. <i>Ultrastructural Pathology</i> , 1992 , 16, 603-14	1.3	22
4	Loss of Y chromosome in gastric carcinoma. Fact or artifact?. <i>Cancer Genetics and Cytogenetics</i> , 1992 , 61, 39-41		16
3	C-erbB-2 expression in primary gastric carcinomas and their metastases. <i>Cancer Genetics and Cytogenetics</i> , 1992 , 63, 121		3
2	Clonal cytogenetic abnormalities and telomeric associations in a fibroxanthoma of the stomach. <i>Genes Chromosomes and Cancer</i> , 1992 , 5, 407-9	5	10
1	c-erbB-2 expression in primary gastric carcinomas and their metastases. <i>Modern Pathology</i> , 1992 , 5, 384-90		36